Sector News

Boston Scientific buys Aran unit LumenR

November 9, 2016
Life sciences

Aran R&D (1982) Ltd.’s share price rose 3% today, after the company reported the sale of LumenR, a subsidiary, to Boston Scientific.

Aran will post an $800,000 capital gain on the sale. LumenR has developed a system for complicated intestinal surgery. The sale agreement includes royalties likely to increase Aran’s profit by up to $2.8 million.

Led by chairman Avraham Zakay and CEO Ran Stav, Aran provides services in product design and development, equipment imports for the plastics industry, and the construction of solar energy stations. In recent years, it has also invested in companies and fostered startups. Four of the medical equipment companies it founded were sold shortly afterwards. The sale prices were low in absolute terms, but the deals yielded fine returns on Aran’s investment. In addition to LumenR, ac Therapies was also sold to Boston Scientific.

In a 2013 “Globes” story, Stav and Zakay explained, “At a certain point, we realized that we had a collection of brilliant engineers, who in one lunch came up with enough ideas to populate an entire incubator, and were capable of developing them. Startups gradually became a larger part of our activity.” One of the first startups in which Aran invested was Percutaneous Valve Technologies (PVT), a pioneer in replacing heart valves through catheterization, a field that has meanwhile become huge. The company was sold to US company Edwards Lifesciences for $155 million, and became that company’s R&D center in Israel. Aran finances its activities without venture capital.

In the first half of 2016, Aran posted a NIS 299,000 profit on NIS 48 million in revenue, up 6%, compared with the corresponding period last year, so the profit on the sale of LumenR is significant for Aran. The Aran share has lost 15% of its value this year, leaving it with a NIS 135 million market cap.

Together with the announcement of its exit, Aran also announced that another subsidiary, Endoaid, in which it has a 66% stake, had signed an agreement for the distribution of its products in Turkey. Endoaid is developing a product placed at the end of a colonscope to enhance the latter’s activity. Aran also owns 50% of Cardiopass, which is developing a special catheter for treating chronic cardiac patients

By Gali Weinreb

Source: Globes

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach